Research Area D: Towards Integrative Therapy Concepts

Central question:

How can discoveries from the other areas be harnessed for innovative microbiome-based diagnostic, preventive, and therapeutic strategies?

Aim

Scientists in Research Area D will translate knowledge acquired in sections A, B and C into innovative, microbiome-centered, and personalized strategies of risk stratification, diagnosis, prevention and therapy against antibiotic-resistant bacterial pathogens (ARBPs). Notably, the resistomes of risk patients will be analyzed by metagenome sequencing of fecal samples and used to implement patient-specific therapies.

 

Moreover, combined resistome data will be used to adjust general antibiotic stewardship guidelines at the University Hospital Tübingen. In parallel, the commensals, the phages and the host-derived antimicrobial molecules with the capacity to selectively eliminate facultative pathogens from human microbiomes such as those identified in Research Area A, B, and C will be tested as promising agents to prevent infections by ARBPs.


Principal Investigators

Prof. Dr. Peter Kremsner

University of Tübingen
Institute for Tropical Medicine, Travel Medicine, Human Parasitology
Webseite

Prof. Dr. Dr. Urban Wiesing

University of Tübingen
Institute for Ethics in Sciences and Humanities
Website